References
- 1. Kosińska J, Billing-Marczak K, Krotkiewski M. Nowopoznana rola witaminy K w patogenezie chorób cywilizacyjnych. Med Rodz 2008;2:48-60.
- 2. Ostrowicz A. Rola i znaczenie witaminy K w organizmie człowieka. http://treepharma.pl/wp-content/uploads/2016/02/Rola-i-znaczenie-Witaminy-K-w-organizmie.pdf (12.03.2018).
- 3. Solgar. Witamina K. https://solgar.pl/leksykon/witamina-k2 (12.03.2018).
- 4. Thijssen HH, Vervoort LM, Schurgers LJ, Shearer MJ. Menadione is a metabolite of oral vitamin K. Br J Nutr 2006;95(2):260-6.10.1079/BJN20051630
- 5. Shea MK, Booth SL, Weiner DE, Brinkley TE, Kanaya AM, Murphy RA, et al. Circulating vitamin K is inversely associated with incident cardiovascular disease risk among those treated for hypertension in the Health, Aging, and Body Composition Study (Health ABC). J Nutr 2017;147(5):888-95.10.3945/jn.117.249375
- 6. van Ballegooijen AJ, Cepelis A, Visser M, Brouwer IA, van Schoor NM, Beu-lens JW. Joint association of low vitamin D and vitamin K status with blood pressure and hypertension. Hypertension 2017;69(6):1165-72.10.1161/HYPERTENSIONAHA.116.08869
- 7. Garcia AA, Reitsma PH. VKORC1 and the vitamin K cycle. Vitam Horm 2008;78:23-33.10.1016/S0083-6729(07)00002-7
- 8. Ciurus T, Lelonek M. Znaczenie polimorfizmów genów VKORC1 oraz CYP2C9 dla leczenia przeciwzakrzepowego doustnymi pochodnymi kumaryny – przegląd doniesień. Folia Cardiologica Excerpta 2012;7(4):189-93.
- 9. Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 pharmacog-enomics summary. Pharmacogenet Genomics 2010;20(10):642-4.10.1097/FPC.0b013e32833433b6308604319940803
- 10. Tsugawa N, Uenishi K, Ishida H, Minekami T, Doi A, Koike S, et al. A novel method based on curvature analysis for estimating the dietary vitamin K requirement in adolescents. Clin Nutr 2012;31(2):255-60.10.1016/j.clnu.2011.10.00622078785
- 11. Lombardi G, Perego S, Luzi L, Banfi G. A four-season molecule: osteocalcin. Updates in its physiological roles. Endocrine 2015;48(2):394-404.10.1007/s12020-014-0401-025158976
- 12. Centi AJ, Booth SL, Gundberg CM, Saltzman E, Nicklas B, Shea MK. Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women. Endocrine 2015;50(3):627-32.10.1007/s12020-015-0618-6464341425963022
- 13. Atkins GJ, Welldon KJ, Wijenayaka AR, Bonewald LF, Findlay DM. Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by γ-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol 2009;297(6):C1358-67.10.1152/ajpcell.00216.200919675304
- 14. Palermo A, Tuccinardi D, D’Onofrio L, Watanabe M, Maggi D, Maurizi AR, et al. Vitamin K and osteoporosis: Myth or reality? Metabolism 2017;70:57-71.
- 15. Ryan-Harshman M, Aldoori W. Bone health. New role for vitamin K? Can Fam Physician 2004;50:993-7.
- 16. Finnes TE, Lofthus CM, Meyer HE, Søgaard AJ, Tell GS, Apalset EM, et al. A combination of low serum concentrations of vitamins K1 and D is associated with increased risk of hip fractures in elderly Norwegians: a NOREPOS study. Osteoporos Int 2016;27(4):1645-52.10.1007/s00198-015-3435-026630974
- 17. Fang Y, Hu C, Tao X, Wan Y, Tao F. Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J Bone Miner Metab 2012;30(1):60-8.10.1007/s00774-011-0287-321674202
- 18. Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int 2015;26(3):1175-86.10.1007/s00198-014-2989-625516361
- 19. Hao G, Zhang B, Gu M, Chen C, Zhang Q, Zhang G, et al. Vitamin K intake and the risk of fractures: A meta-analysis. Medicine (Baltimore) 2017;96(17):e6725.10.1097/MD.0000000000006725541325428445289
- 20. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Vitamin K2 induces phosphorylation of protein kinase A and expression of novel target genes in osteoblastic cells. J Mol Endocrinol 2007;39(4):239-47.10.1677/JME-07-004817909264
- 21. Ebina K, Noguchi T, Hirao M, Kaneshiro S, Tsukamoto Y, Yoshikawa H. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. J Bone Miner Metab 2016;34(3):243-50.10.1007/s00774-015-0710-226303222
- 22. Iwamoto J, Takeda T, Sato Y. Prevention and treatment of corticosteroid--induced osteoporosis. Yonsei Med J 2005;46(4):456-63.10.3349/ymj.2005.46.4.456281582816127768
- 23. Sanguineti R, Monacelli F, Parodi A, Furfaro AL, Borghi R, Pacini D, et al. Vitamins D3 and K2 may partially counterbalance the detrimental effects of pentosidine in ex vivo human osteoblasts. J Biol Regul Homeost Agents 2016;30(3):713-26.
- 24. Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem 2006;281(25):16927-34.10.1074/jbc.M60089620016606623
- 25. Zhang Y, Weng S, Yin J, Ding H, Zhang C, Gao Y. Vitamin K2 promotes mesenchymal stem cell differentiation by inhibiting miR-133a expression. Mol Med Rep 2017;15(5):2473-80.10.3892/mmr.2017.6308542886728447758
- 26. Sung B, Oyajobi B, Aggarwal BB. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther 2012;11(2):350-9.10.1158/1535-7163.MCT-11-0731327766322090419
- 27. Neogi T, Booth SL, Zhang YQ, Jacques PF, Terkeltaub R, Aliabadi P, et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum 2006;54(4):1255-61.10.1002/art.2173516572460
- 28. Shea MK, Kritchevsky SB, Hsu FC, Nevitt M, Booth SL, Kwoh CK, et al. The association between vitamin K status and knee osteoarthritis features in older adults: the Health, Aging and Body Composition Study. Osteoarthritis Cartilage 2015;23(3):370-8.10.1016/j.joca.2014.12.008433950725528106
- 29. Rafael MS, Cavaco S, Viegas CS, Santos S, Ramos A, Willems BA, et al. Insights into the association of Gla-rich protein and osteoarthritis, novel splice variants and γ-carboxylation status. Mol Nutr Food Res 2014;58(8):1636-46.10.1002/mnfr.20130094124867294
- 30. Han JM, Jo AN, Lee SM, Bae HS, Jun DW, Cho YK, et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2014;29(6):1265-72.10.1111/jgh.1252024955455
- 31. Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 2006;106(4):867-72.10.1002/cncr.2166716400650
- 32. Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, et al. Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway. Anticancer Drugs 2005;16(8):837-44.10.1097/01.cad.0000175583.78574.d716096431
- 33. Ide Y, Zhang H, Hamajima H, Kawaguchi Y, Eguchi Y, Mizuta T, et al. Inhibition of matrix metalloproteinase expression by menatetrenone, a vitamin K2 analogue. Oncol Rep 2009;22(3):599-604.
- 34. Azuma K, Urano T, Ouchi Y, Inoue S. Vitamin K2 suppresses proliferation and motility of hepatocellular carcinoma cells by activating steroid and xenobiotic receptor. Endocr J 2009;56(7):843-9.10.1507/endocrj.K09E-108
- 35. Ha TY, Hwang S, Hong HN, Choi YI, Yoon SY, Won YJ, et al. Synergistic effect of sorafenib and vitamin K on suppression of hepato-cellular carcinoma cell migration and metastasis. Anticancer Res 2015;35(4):1985-95.
- 36. Wei G, Wang M, Hyslop T, Wang Z, Carr BI. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 2010;127(12):2949-58.10.1002/ijc.25498295518521351273
- 37. Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, et al. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J Hepatol 2009;51(2):315-21.10.1016/j.jhep.2009.04.01119501932
- 38. Zhang H, Ozaki I, Hamajima H, Iwane S, Takahashi H, Kawaguchi Y, et al. Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. Oncol Rep 2011;25(1):159-66.
- 39. Avior Y, Levy G, Zimerman M, Kitsberg D, Schwartz R, Sadeh R, et al. Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes. Hepatology 2015;62(1):265-78.10.1002/hep.2780325808545
- 40. Zhang YS, Chu JH, Cui SX, Song ZY, Qu XJ. Des-γ-carboxy prothrombin (DCP) as a potential autologous growth factor for the development of hepatocellular carcinoma. Cell Physiol Biochem 2014;34(3):903-15.10.1159/00036630825200250
- 41. Hitomi M, Nonomura T, Yokoyama F, Yoshiji H, Ogawa M, Nakai S, et al. In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma. Int J Oncol 2005;26(5):1337-44.10.3892/ijo.26.5.1337
- 42. Hitomi M, Yokoyama F, Kita Y, Nonomura T, Masaki T, Yoshiji H, et al. Anti-tumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol 2005;26(3):713-20.
- 43. Setoguchi S, Watase D, Matsunaga K, Matsubara M, Kubo Y, Kusuda M, et al. Enhanced antitumor effects of novel intracellular delivery of an active form of menaquinone-4, menahydroquinone-4, into hepatocellular carcinoma. Cancer Prev Res (Phila) 2015;8(2):129-38.10.1158/1940-6207.CAPR-14-029225416411
- 44. Caviglia GP, Abate ML, Gaia S, Petrini E, Bosco C, Olivero A, et al. A Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Med 2017;59(4):283-9.10.23736/S0031-0808.17.03353-528650134
- 45. Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G, et al. PIVKA-II is a useful tool for diagnostic characterization of ultra-sound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) 2017;96(26):e7266.10.1097/MD.0000000000007266550004328658121
- 46. Ismail MM, Morsi HK, Abdulateef NA, Noaman MK, Abou El-Ella GA. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. Scand J Clin Lab Invest 2017;77(3):175-83.10.1080/00365513.2017.128668428276727
- 47. Nanashima A, Taura N, Abo T, Ichikawa T, Sakamoto I, Nagayasu T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Dig Dis Sci 2011;56(10):3086-100.10.1007/s10620-011-1796-621706206
- 48. Hayashi M, Shimizu T, Hirokawa F, Inoue Y, Komeda K, Asakuma M, et al. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma. Am Surg 2011;77(5):572-8.10.1177/000313481107700516
- 49. Bae HM, Lee JH, Yoon JH, Kim YJ, Heo DS, Lee HS. Protein induced by vita-min K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer 2011;11:435.10.1186/1471-2407-11-435321010821985636
- 50. Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 2010;17(5):527-32.10.1007/s00534-009-0162-y19707711
- 51. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010;102(5):462-810.1002/jso.2163120872949
- 52. Krzyżanowska P, Drzymała-Czyż S, Pogorzelski A, Duś-Żuchowska M, Skorupa W, Bober L, et al. Vitamin K status in cystic fibrosis patients with liver cirrhosis. Dig Liver Dis 2017;49(6):672-5.10.1016/j.dld.2017.01.15528185838
- 53. Głowacki Ł. Działanie plejotropowe witaminy K – suplementować czy nie suplementować? http://biotechnologia.pl/farmacja/dzialanie-plejotropowe-witaminy-k-suplementowac-czy-nie-suplementowac,17226 (19.07.2017).
- 54. Sakaue M, Mori N, Okazaki M, Kadowaki E, Kaneko T, Hemmi N, et al. Vita-min K has the potential to protect neurons from methylmercury-induced cell death in vitro. J Neurosci Res 2011;89(7):1052-8.10.1002/jnr.2263021488088
- 55. Delwar ZM, Avramidis D, Follin E, Hua Y, Siden Å, Cruz M, et al. Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells. Invest New Drugs 2012;30(4):1302-10.10.1007/s10637-011-9680-y21553345
- 56. Tsujioka T, Miura Y, Otsuki T, Nishimura Y, Hyodoh F, Wada H, et al. The mechanisms of vitamin K2-induced apoptosis of myeloma cells. Haematologica 2006;91(5):613-9.
- 57. Kiely M, Hodgins SJ, Merrigan BA, Tormey S, Kiely PA, O’Connor EM. Real--time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutr Res 2015;35(8):736-43.10.1016/j.nutres.2015.05.01426082424